Autologous Bone Marrow Transplantation - Blog Science Connections

Chemoimmunoseparation of T Lymphoma Cells
From Human Bone Marrow
Robert Bast, Jr., Bruce Montgomery, Azeem Haleem,
Joanne Kurtzberg, Ann Rhinehardt-Clark,
Sundaram Ramakrishnan, Greg Olsen,
Carol Smith, David Leslie, William Peters,
and Lou Houston
One requirement for effective autologous bone marrow transplantation ( ABMT)
in leukemia and lymphoma is the complete and selective elimination of
malignant cells from remission bone marrow. In early studies we optimized
removal of nonlymphocytic leukemic cells from rat bone marrow using
polyclonal antibodies and complement (1). Availability of monoclonal antibodies
reactive with determinants expressed by leukemias and lymphomas in
the B-cell lineage facilitated attempts to eliminate tumor cells that tests showed
positive for the common acute lymphoblastic leukemic antigen (CALLA) from
human bone marrow (2). Limiting dilution techniques were utilized to estimate
clonogenic Burkitt's lymphoma cells that remained following treatment with
monoclonal antibodies and rabbit complement (3). The use of multiple
monoclonal antibodies proved superior to treatment with single antibodies (3).
Using optimal combinations of two monoclonals, about 3.5 logs of malignant
clonogenic cells could be removed without affecting growth of granulocytemacrophage
colony-forming units (CFCIs-GM), erythroid burst-forming units
347